| Literature DB >> 28285701 |
Stéphane Holbrechts1, Julie Gorham2, Spyridon Sideris2, Anne-Pascale Meert3, Valérie Durieux4, Thierry Berghmans3, Jean-Paul Sculier5.
Abstract
The development of new immune treatment in oncology and particularly for lung cancer may induce new complications, particularly activation or reactivation of auto-immune diseases. In this context, a systematic review on the auto-immune paraneoplastic syndromes associated with lung cancer appears useful. This article is the second of a series of five and deals with hematologic, cutaneous and vascular syndromes.Entities:
Mesh:
Year: 2017 PMID: 28285701 DOI: 10.1016/j.lungcan.2017.01.016
Source DB: PubMed Journal: Lung Cancer ISSN: 0169-5002 Impact factor: 5.705